CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.
The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells. Multikine has been evaluated in a pivotal Phase III clinical trial, and CEL-SCI has conducted additional clinical studies and manufacturing development to support potential registration in the United States and abroad. Beyond Multikine, the company is advancing early-stage programs in infectious disease and oncology that leverage its expertise in immune modulation.
CEL-SCI has carried out clinical trials and manufacturing activities in multiple regions, including North America, Europe, Latin America and South Africa. Its research and development operations encompass in-house laboratories in Virginia and collaborations with contract research organizations around the world. This global footprint reflects the company’s commitment to rigorous clinical testing and regulatory engagement in key markets.
Under the leadership of President and Chief Executive Officer Geert Kersten, CEL-SCI maintains a small executive team supported by a board of directors with expertise in biotechnology, clinical operations and regulatory affairs. The company’s scientific staff comprises immunologists, process development specialists and clinical trial managers who collectively steer CEL-SCI’s programs from preclinical research through late-stage development.
AI Generated. May Contain Errors.
Free CVM Stock Alerts